The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Chirality of New Drug Approvals (2013–2022): Trends and Perspectives
Open accessAbstract
Many drugs are chiral with their chirality determining their biological interactions, safety, and efficacy. Since the 1980s, there has been a regulatory preference to bring single enantiomer to market. This perspective discusses trends related to chirality that have developed in the past decade (2013-2022) of new drug approvals. The EMA has not approved a racemate since 2016, while the average for the FDA is one per year from 2013 to 2022. These 10 include drugs which have been previously marketed elsewhere for several decades, analogues of pre-existing drugs, or drugs where the undefined stereocenter does not play a role in therapeutic activity. Two chiral switches were identified which were both combined with drug repurposing. This combination strategy has the potential to produce therapeutically valuable drugs in a faster time frame. Two class III atropisomers displaying axial chirality were approved between 2013 and 2022, one as a racemate and one as a single enantiomer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Aromatic Amino Acids and Modification of Parkinsonism
Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702162760703 · Cited by 1,494
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,284
Laboratory of Toxicology, F. O. P., Chuong, P.-H., Nguyen, L. A., Department of Pharmacy, L. S. P. C. H., He, H., & Department of Analytical Chemistry, C. P. U. (2006) · International Journal of Biomedical Science · doi:10.59566/ijbs.2006.2085 · Cited by 1,224
Basic terminology of stereochemistry (IUPAC Recommendations 1996)
Moss, G. P. (1996) · Pure and Applied Chemistry · doi:10.1351/pac199668122193 · Cited by 883
Assessing Atropisomer Axial Chirality in Drug Discovery and Development
LaPlante, S. R., Fader, L. D., Fandrick, K. R., Fandrick, D. R., Hucke, O., Kemper, R., Miller, S. P. F., & Edwards, P. J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200584g · Cited by 861
Evaluation and Treatment of Chagas Disease in the United States: A Systematic Review
Bern, C., Montgomery, S. P., Herwaldt, B. L., Rassi, A., Marin-Neto, J. A., Dantas, R. O., Maguire, J. H., Acquatella, H., Morillo, C., Kirchhoff, L. V., et al. (2007) · JAMA · doi:10.1001/jama.298.18.2171 · Cited by 775
25 Years of Proton Pump Inhibitors: A Comprehensive Review
Strand, D. S., Kim, D., & Peura, D. A. (2017) · Gut and Liver · doi:10.5009/gnl15502 · Cited by 671
Putting chirality to work: the strategy of chiral switches
Agranat, I., Caner, H., & Caldwell, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd915 · Cited by 637
Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology
Ari�ns, E. J. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541922 · Cited by 609
Chiral Toxicology: It's the Same Thing…Only Different
Smith, S. W. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp097 · Cited by 602
The market of chiral drugs: Chiral switches versus de novo enantiomerically pure compounds
Calcaterra, A., & D’Acquarica, I. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.07.008 · Cited by 481
A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole
Olbe, L., Carlsson, E., & Lindberg, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1010 · Cited by 418
COMPARATIVE PHARMACOLOGY OF THE KETAMINE ISOMERS
WHITE, P. F., SCHÜTTLER, J., SHAFER, A., STANSKI, D. R., HORAI, Y., & TREVOR, A. J. (1985) · British Journal of Anaesthesia · doi:10.1093/bja/57.2.197 · Cited by 415
Atropisomerism in Medicinal Chemistry: Challenges and Opportunities
Toenjes, S. T., & Gustafson, J. L. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0152 · Cited by 382
Atropisomerism in the Pharmaceutically Relevant Realm
Basilaia, M., Chen, M. H., Secka, J., & Gustafson, J. L. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00500 · Cited by 326
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo
Abbas, A. I., Hedlund, P. B., Huang, X.-P., Tran, T. B., Meltzer, H. Y., & Roth, B. L. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1521-8 · Cited by 285
Ebert, B., Mikkelsen, S., Thorkildsen, C., & Borgbjerg, F. M. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01116-3 · Cited by 270
Auclair, A. L., Martel, J. C., Assié, M. B., Bardin, L., Heusler, P., Cussac, D., Marien, M., Newman-Tancredi, A., O'Connor, J. A., & Depoortère, R. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.02.024 · Cited by 263
Intravenous arketamine for treatment-resistant depression: open-label pilot study
Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01110-5 · Cited by 257
Driessen, B., & Reimann, W. (1992) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1992.tb14226.x · Cited by 238
Panobinostat: First Global Approval
Garnock-Jones, K. P. (2015) · Drugs · doi:10.1007/s40265-015-0388-8 · Cited by 212
l-Nucleoside enantiomers as antivirals drugs: A mini-review
Mathé, C., & Gosselin, G. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.04.017 · Cited by 196
A Look at the Importance of Chirality in Drug Activity: Some Significative Examples
Ceramella, J., Iacopetta, D., Franchini, A., Luca, M. D., Saturnino, C., Andreu, I., Sinicropi, M. S., & Catalano, A. A. (2022) · Applied Sciences · doi:10.3390/app122110909 · Cited by 175
Gorman, J. M., Korotzer, A., & Su, G. (2002) · CNS Spectrums · doi:10.1017/s1092852900028595 · Cited by 169
A historical review of antidepressant effects of ketamine and its enantiomers
Wei, Y., Chang, L., & Hashimoto, K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172870 · Cited by 169
Synthetic Approaches to the New Drugs Approved During 2015
Flick, A. C., Ding, H. X., Leverett, C. A., Kyne, R. E., Liu, K. K. ‐., Fink, S. J., & O’Donnell, C. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00010 · Cited by 159
Chiral Switch: Between Therapeutical Benefit and Marketing Strategy
Hancu, G., & Modroiu, A. (2022) · Pharmaceuticals · doi:10.3390/ph15020240 · Cited by 154
Tucker, G. T. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02047-x · Cited by 151
Rise and fall of anti-obesity drugs
Li, M., & Cheung, B. M. (2011) · World Journal of Diabetes · doi:10.4239/wjd.v2.i2.19 · Cited by 131
Jacques, V., Czarnik, A. W., Judge, T. M., der Ploeg, L. H. T. V., & DeWitt, S. H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417832112 · Cited by 118
Chirality: a blueprint for the future
Burke, D. L., & Henderson, D. J. (2002) · British Journal of Anaesthesia · doi:10.1093/bja/88.4.563 · Cited by 112
Stereoselectivity in the Pharmacodynamics and Pharmacokinetics of the Chiral Antimalarial Drugs
Brocks, D. R., & Mehvar, R. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00004 · Cited by 110
Lesinurad: First Global Approval
Hoy, S. M. (2016) · Drugs · doi:10.1007/s40265-016-0550-y · Cited by 107
Lanman, B. A., Parsons, A. T., & Zech, S. G. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00479 · Cited by 106
Baumann, P., ZULLINO, D. F., & Eap, D. C. B. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00051-2 · Cited by 95
Mercurio, A., Adriani, G., Catalano, A. A., Carocci, A., Rao, L., Lentini, G., Cavalluzzi, M. M., Franchini, C., Vacca, A., & Corbo, F. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170601074646 · Cited by 86
The predicated demise of racemic new molecular entities is an exaggeration
Agranat, I., Wainschtein, S. R., & Zusman, E. Z. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3657-c1 · Cited by 85
New, but Not Improved? Incorporating Comparative-Effectiveness Information into FDA Labeling
Stafford, R. S., Wagner, T. H., & Lavori, P. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0906490 · Cited by 78
Comparison of escitalopram and citalopram efficacy: A meta-analysis
Auquier, P., Robitail, S., Llorca, P., & Rive, B. (2003) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500310003408 · Cited by 76
Impact of Stereoselectivity on the Pharmacokinetics and Pharmacodynamics of Antiarrhythmic Drugs
Mehvar, R., Brocks, D., & Vakily, M. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241080-00001 · Cited by 68
Baker, G. B., & Prior, T. I. (2002) · Annals of Medicine · doi:10.1080/078538902321117742 · Cited by 68
Three‐Dimensional Pharmacology, a Subject Ranging from Ignorance to Overstatements
Waldeck, B. (2003) · Pharmacology & Toxicology · doi:10.1046/j.1600-0773.2003.pto930502.x · Cited by 58
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
Findling, R. L., Candler, S. A., Nasser, A. F., Schwabe, S., Yu, C., Garcia-Olivares, J., O’Neal, W., & Newcorn, J. H. (2021) · CNS Drugs · doi:10.1007/s40263-021-00825-w · Cited by 55
Isavuconazonium: First Global Approval
McCormack, P. L. (2015) · Drugs · doi:10.1007/s40265-015-0398-6 · Cited by 54
Mansfield, P. R., Henry, D. A., & Tonkin, A. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443050-00002 · Cited by 53
Branch, S. K., & Agranat, I. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm402001w · Cited by 50
Stoschitzky, K., Lindner, W., Egginger, G., et al. (1992) · Clinical pharmacology and therapy · doi:10.1038/clpt.1992.45 · Cited by 47
Stereochemical facets of clinical β‐blockers: An overview
Vashistha, V. K., & Kumar, A. (2020) · Chirality · doi:10.1002/chir.23200 · Cited by 46
An in vitro model to evaluate the impact of environmental fine particles (PM0.3-2.5) on skin damage
Verdin, A., Cazier, F., Fitoussi, R., Blanchet, N., Vié, K., Courcot, D., Momas, I., Séta, N., & Achard, S. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.01.016 · Cited by 45
Repurposing of Drugs–The Ketamine Story
Das, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01193 · Cited by 45
Chiral Organophosphorus Pharmaceuticals: Properties and Application
Kolodiazhna, A. О., & Kolodiazhnyi, O. I. (2023) · Symmetry · doi:10.3390/sym15081550 · Cited by 37
How the Chemical Properties of GBCAs Influence Their Safety Profiles In Vivo
Do, Q. N., Lenkinski, R. E., Tircsó, G., & Kovács, Z. Z. (2021) · Molecules · doi:10.3390/molecules27010058 · Cited by 36
The Quest for Secondary Pharmaceuticals: Drug Repurposing/Chiral-Switches Combination Strategy
D’Acquarica, I., & Agranat, I. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00151 · Cited by 34
Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome
Buck, M. L., & Goodkin, H. P. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019856008 · Cited by 31
Gillis, E. P., Parcella, K., Bowsher, M., Cook, J. H., Iwuagwu, C. I., Naidu, B. N., Patel, M., Peese, K. M., Huang, H., Valera, L., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01732 · Cited by 31
Anderson, K. S. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00092-3 · Cited by 30
Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
Famiglini, V., & Silvestri, R. (2016) · Molecules · doi:10.3390/molecules21020221 · Cited by 29
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors
Long, A. S., Zhang, A. D., Meyer, C., Egilman, A. C., Ross, J. S., & Wallach, J. D. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.5731 · Cited by 25
Li, J., Nelis, M., Sourbron, J., Copmans, D., Lagae, L. G., Cabooter, D., & de Witte, P. A. M. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03358-2 · Cited by 24
Pomalidomide: A Review of Its Use in Patients with Recurrent Multiple Myeloma
Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0196-6 · Cited by 20
Grattan, V. T., Vaino, A. R., Prensky, Z., & Hixon, M. S. (2019) · ACS Omega · doi:10.1021/acsomega.9b02144 · Cited by 18
Fox, G. M., & Kranke, P. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1750366 · Cited by 11
Cited by
Marshall, C. M., Federice, J. G., Bell, C. N., Cox, P. B., & Njardarson, J. T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01122 · Cited by 1,064
Metadata
- Authors
- McVicker, R. U., & O’Boyle, N. M.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2024-02-12
- Volume
- 67
- Issue
- 4
- Pages
- 2305-2320
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4391752837
- Cited by
- 255
- References
- 64
- FWCI
- 35.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.